Etanercept Shortage Update: What Patients Need to Know in 2026

If you're a patient who depends on etanercept (Enbrel) to manage rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, or ankylosing spondylitis, you may have experienced frustrating access issues. Refill delays, insurance denials, specialty pharmacy headaches — it can feel like your medication is perpetually hard to get. So what's actually going on in 2026?

Is Etanercept in an FDA-Declared Shortage in 2026?

No. As of 2026, etanercept is not listed on the FDA's Drug Shortage Database. Amgen and Pfizer continue to manufacture Enbrel, and the drug is not experiencing a supply-side manufacturing disruption the way some other medications have in recent years.

But "not in FDA shortage" doesn't mean "easy to get." The real barriers to etanercept access are structural — built into the drug's specialty pharmacy distribution model, its insurance coverage requirements, and the sustained absence of any US biosimilar competition.

What's Actually Driving Etanercept Access Problems?

Several factors make etanercept harder to access than most prescription medications:

Specialty pharmacy-only distribution. Etanercept must be refrigerated and is too costly for most retail pharmacies to stock. It's dispensed almost exclusively through specialty mail-order pharmacies.

Universal prior authorization requirements. Every insurance plan requires prior authorization for etanercept. These expire and must be renewed. New plans, job changes, or insurance switches can trigger new PA processes and weeks-long gaps.

No US biosimilars until 2029. Two FDA-approved etanercept biosimilars (Erelzi, Eticovo) exist but cannot be sold in the US due to an Amgen patent that runs through 2029. No biosimilar competition means no price competition — etanercept list prices remain around $8,000 per month.

Step therapy requirements. Many insurance plans require patients to first try (and fail on) conventional DMARDs like methotrexate before approving a biologic like etanercept. This can delay initial access by months.

Will Biosimilars Be Available in 2026?

Unfortunately, no. Two biosimilars — Erelzi (etanercept-szzs) by Sandoz and Eticovo (etanercept-ykro) by Samsung Bioepis — received FDA approval in 2016 and 2019 respectively. But both companies lost patent challenges against Amgen, and neither product will enter the US market until 2029 at the earliest.

This is a significant issue for patients and payers. In the European Union, etanercept biosimilars have been available since 2016 and have dramatically lowered costs. US patients, blocked by Amgen's patent enforcement, won't see that relief until the next decade.

Medicare Negotiations and Price Changes in 2026

One piece of good news for Medicare patients: the Centers for Medicare & Medicaid Services (CMS) selected etanercept as one of 10 drugs for government price negotiation under the Inflation Reduction Act. The negotiated price for Medicare is targeted at around $2,355 per month — lower than the current list price, though still substantial. Combined with the $2,000 annual out-of-pocket cap for Medicare Part D that took effect in 2025, Medicare patients have better financial protection than in previous years.

What Should Patients Do Right Now?

Given the access landscape in 2026, here are the most important steps for patients who take etanercept:

Check your prior authorization status. Know when it expires and begin renewal at least 3-4 weeks early. Don't wait for your pharmacy to tell you — be proactive.

Enroll in Enbrel SupportPlus. Amgen's dedicated program can help manage prior authorizations, connect you with financial assistance, and provide a nurse case manager.

Apply for financial assistance if needed. The Amgen Safety Net Foundation may provide free medication to qualifying patients. Commercial insurance patients can use the Enbrel copay card to reduce costs to as little as $0 per month.

Have a backup plan. Talk to your doctor now about what alternative therapy to use if etanercept becomes unavailable. A pre-authorized alternative can save weeks of delays.

Use medfinder if you're stuck. medfinder calls pharmacies near you to check which ones can fill your etanercept prescription, so you don't have to spend hours on the phone yourself.

Looking Ahead: When Will Things Get Easier?

The most meaningful change for US patients will come in 2029, when biosimilar competition is expected to enter the market and potentially drive down prices significantly — similar to what happened with Humira biosimilars in 2023. Until then, the strategies above are your best tools. If you're exploring other options now, see our guide: alternatives to etanercept if you can't fill your prescription.